Research paperEx-vivo α-Galactosylceramide activation of NKT cells in humans and macaques
Introduction
NKT cells are lymphocytes of the innate immune system that are important in viral and antitumor immunity through their ability to be rapidly activated and express a wide range of effector molecules (Lindqvist et al., 2009, Motohashi et al., 2009, Brigl and Brenner, 2010, Fujii et al., 2010). NKT cells are activated via an antigen-specific T cell receptor (TCR). Improved methodologies to assess the activation of NKT cells ex vivo should assist dissecting the importance of these immune cells in humans and non-human primates.
Type I or semi-invariant NKT cells express an invariant TCR-α chain (Vα14-Jα18 in mice, Vα24-Jα18 in humans) and are restricted by the MHC-class Ib molecule, CD1d, expressed on APCs presenting lipid based antigens such as glycolipid antigens (Exley et al., 1997). Lipid based antigens are presented to NKT cells by direct ligation onto surface CD1d molecules or internalized into endosomes where loading onto CD1d occurs and subsequent membrane surface presentation on a lipid raft (Venkataswamy and Porcelli, 2010). NKT cells respond to a broad variety of lipid-based antigens including self and foreign glycolipid and phospholipid antigens (Venkataswamy and Porcelli, 2010). α-galactosylceramide (α-GalCer) is a synthetic glycosphingolipid derived from the marine sponge, Agelas mauritianus, and is commonly used in mice and human NKT studies as a potent activator of NKT cells in vivo or in vitro (Kawano et al., 1997). α-GalCer has immunomodulatory effects in cancer immunotherapy (Giaccone et al., 2002, Chang et al., 2005, Uchida et al., 2008, Kunii et al., 2009, Motohashi et al., 2009, Schneiders et al., 2011, Yamasaki et al., 2011, Vivier et al., 2012), autoimmunity (Novak and Lehuen, 2011, Hong et al., 2001, Wu and Van Kaer, 2009), bacterial (Brigl and Brenner, 2010, Emoto et al., 2010), and viral infections (Guillonneau et al., 2009, Lindqvist et al., 2009, Schneiders et al., 2011).
Upon activation with α-GalCer, NKT cells produce large amounts of Th1, Th2 and Th17 cytokines such as IFNγ, TNF, IL-2, IL-4, IL-10, IL-13, IL-17, IL-21 and IL-22 (Godfrey et al., 2010). The cytokines produced by NKT cells trigger the activation of other cells of the immune system such as NK cells, T and B cells and DCs (Fujii et al., 2003, Cerundolo et al., 2009). The detection of the expression of these cytokines by intracellular cytokine staining and flow cytometry permits an analysis of NKT cell functional status.
Studies on α-GalCer activation of mice NKT cells often involve in vivo activation, where α-GalCer induced cytokine production by NKT cells, and indirectly downstream by NK cells, is measured in serum (Sullivan et al., 2010), or directly ex-vivo following α-GalCer administration in vivo (Wilson et al., 2003, Uldrich et al., 2005). In the latter case mice are administered α-GalCer, organs such as spleen, liver or lymph node are harvested a few hours after challenge and the relevant cells placed in culture with a protein transport inhibitor, without any further activation. Alternatively, the global mitogen-induced activation of NKT cells ex vivo is often assessed by PMA/ionomycin stimulation. Such mitogenic stimulation, while providing information on the total functional potential of NKT cells, may not reflect the in vivo capacity of NKT cells when interacting with antigen presented by CD1d. Furthermore, activation with PMA/ionomycin poses difficulties in enumerating intracellular cytokine production from NKT cell subsets as the CD4 surface marker is downregulated upon mitogenic stimulation (O'Neil-Andersen and Lawrence, 2002). Many other studies have assessed activation of mouse NKT cells ex vivo with α-GalCer in combination with protein transport inhibitors such as monensin to detect intracellular cytokines produced in vitro (Uldrich et al., 2005, Patel et al., 2011).
It is important to translate advances in understanding NKT cell biology in mice towards more directly relevant non-human primate models and humans. For example, there is considerable interest in harnessing the antiviral activity of NKT cells in the setting of chronic viral infections such as HIV infection of humans or SIV infection of macaques (Fernandez et al., 2009, Snyder-Cappione et al., 2009). However, such studies require ex vivo/in vitro analysis of NKT cells, yet at present the literature is lacking in clearly defined optimized methods for acute ex-vivo activation of NKT cells with α-GalCer either in humans or macaques. The relative ability of fresh blood NKT cells to respond to acute ex vivo activation with cognate ligands such as α-GalCer has not been studied in HIV infection, or SIV infection, compared to naïve SIV uninfected macaques. Such assays would be useful in immunotherapy or vaccine clinical or pre-clinical trials designed to harness NKT cell based immunity. In this study we assessed ex vivo NKT function upon stimulation of human and macaque blood with α-GalCer under a variety of experimental conditions to optimize methods for NKT cell activation.
Section snippets
Healthy human subjects and animals
For all studies on optimized NKT cell activation methods (Fig. 2, Fig. 3, Fig. 4, Fig. 5) we studied subjects and animals as detailed below. Healthy HIV uninfected human volunteers (n = 5 aged 23–48 years; four females, one male) with varying frequencies of peripheral NKT cells (range of 0.03%-0.23%) were recruited for this study. We also studied a total of 9 juvenile pigtail macaques (Macaca nemestrina) aged 2 to 6 years. Five macaques were infected with SIVmac251 intravaginally and were 21–28
Activation of NKT cells in macaques using standard conditions studied in mice
Our goal was to develop reliable conditions to assess antigen-specific NKT cell activation in macaque or human blood samples. To assess the ability of primate NKT cells to respond to α-GalCer-induced activation ex vivo, we first assayed the effectiveness of the same experimental conditions used in mouse lymphoid cells (Uldrich et al., 2005, Patel et al., 2011) on the ex vivo activation of pigtail macaque or human peripheral blood NKT cells. We gated on NKT cells as previously described (
Discussion
The ability of NKT cells to rapidly respond with production of a variety of cytokines and other effector functions is key to their potent antiviral and anti-tumor properties. The study of antigen-driven NKT cell activation in macaque and human whole blood samples is hampered by relatively weak cytokine responses, compared to similar assays using mouse NKT cells. We refined and optimized methods to study activation of human or macaque NKT cells with the prototypic ligand, α-Galactosylceramide.
Acknowledgments
We thank Wendy Winnall, Konstantinos Kyparissoudis, Angela Chan, Sheilajen Alcantara, Pradeep Sidana, and Megan Schepers for expert assistance and advice. This research was supported by Australian National Health and Medical Research (NHMRC) awards 510448, 629000 and 454569. GC is supported by a Cancer Research Institute postgraduate scholarship. DIG is supported by an NHMRC research fellowship 454309; SJK is supported by an NHMRC research fellowship 508937.
References (44)
- et al.
How invariant natural killer T cells respond to infection by recognizing microbial or endogenous lipid antigens
Semin. Immunol.
(2010) - et al.
Adjuvant activity mediated by iNKT cells
Semin. Immunol.
(2010) - et al.
SIV infection of rhesus macaques results in dysfunctional T- and B-cell responses to neo and recall Leishmania major vaccination
Blood
(2011) - et al.
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis
Lancet
(2008) - et al.
Mechanism of regulation of autoimmunity by iNKT cells
CYTOKINE; MAR
(2011) - et al.
Brefeldin A, but not monensin, completely blocks CD69 expression on mouse lymphocytes: efficacy of inhibitors of protein secretion in protocols for intracellular cytokine staining by flow cytometry
J. Immunol. Methods
(1999) - et al.
Clinical experience with alpha-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection
Clin. Immunol.
(2011) - et al.
Lipid and glycolipid antigens of CD1d-restricted natural killer T cells
Semin. Immunol.
(2010) - et al.
Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy
Clin. Immunol.
(2011) - et al.
In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers
J. Exp. Med.
(2000)
Harnessing invariant NKT cells in vaccination strategies
Nat. Rev. Immunol.
Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients
J. Exp. Med.
Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus
J. Virol.
Human natural killer T cells are heterogeneous in their capacity to reprogram their effector functions
PLoS One
Alpha-GalCer ameliorates listeriosis by accelerating infiltration of Gr-1 + cells into the liver
Eur. J. Immunol.
Requirements for CD1d recognition by human invariant Valpha24 + CD4 − CD8 − T cells
J. Exp. Med.
Peripheral NKT cells in simian immunodeficiency virus-infected macaques
J. Virol.
Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein
J. Exp. Med.
Phenotypic and functional characterization of long-term cultured rhesus macaque spleen-derived NKT cells
J. Immunol.
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors
Clin. Cancer Res.
Raising the NKT cell family
Nat. Immunol.
Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity
Proc. Natl. Acad. Sci. U. S. A.
Cited by (15)
iNKT cells ameliorate human autoimmunity: Lessons from alopecia areata
2018, Journal of AutoimmunityCitation Excerpt :Similarly, when the injection of α-GalCer into skin xenografts was performed subsequent to the IL-2-activated PBMC injection, the development of AA lesions was also prevented (Supplementary Fig. 1). Based on previous work [28,32,33], this suggested the hypothesis that the AA-like phenotype might have been prevented by an α-GalCer-induced expansion of iNKT cell regulatory activity [34,35]. This hypothesis was probed by assessing whether the AA-protective effect of α-GalCer was lost when iNKT cells were depleted by magnetic beads (using the anti-NKT cell TCR antibody, 6B11) prior to PBMCs injection into the human scalp skin grafts (Fig. 1 D; Supplementary Fig. 1), or when NKT TCR-blocking antibody was added to the PBMCs cell culture (Fig. 1 E; Supplementary Fig. 1).
The role of natural killer T cells in liver transplantation
2023, Frontiers in Cell and Developmental BiologyNew insights into iNKT cells and their roles in liver diseases
2022, Frontiers in Immunology